Quick Answer
Syndax Pharmaceuticals Inc reported Operating Income Loss of -$273.08 million for the year ending 2025.
- Syndax Pharmaceuticals Inc showed an increase of +19.6% in Operating Income Loss from 2024 to 2025.
- This data is from Syndax Pharmaceuticals Inc's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Syndax Pharmaceuticals Inc's Operating Income Loss has declined by 1,180.2%.
- Historical annual values: Fiscal year 2025: -$273.08 million | Fiscal year 2024: -$339.67 million | Fiscal year 2023: -$229.95 million | Fiscal year 2022: -$151.76 million | Fiscal year 2021: $26.22 million | Fiscal year 2020: -$71.42 million | Fiscal year 2019: -$57.54 million | Fiscal year 2018: -$75.88 million | Fiscal year 2017: -$61.95 million | Fiscal year 2016: -$43.77 million | Fiscal year 2015: -$20.51 million | Fiscal year 2014: -$21.33 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: